Key Points Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Eli Lilly and Almirall’s Ebglyss (lebrikizumab) has been shown to significantly improve the signs and symptoms of atopic ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company (NYSE:LLY) is one of the stocks in Jim Cramer’s spotlight. Answering a caller’s query about the company ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

David Mooney, who most recently served as Chief of Cyber Protective Services at the Cybersecurity and Infrastructure Security ...

President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports. Lilly's margins could be negatively ...